Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-25 · 1009 Präparate · 54812 Quellenpassagen · 148 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Wechselwirkungen · Prezista
PREZISTA 100 mg/ml oral suspension · Abschnitt 4.5 · PDF-Seite 17
HOS-116371 · Präparat HOS-094447
The use of carbamazepine with
PREZISTA co-administered with
cobicistat is contraindicated (see
section 4.3).
Clonazepam Not studied. Co-administration of Clinical monitoring is
boosted PREZISTA with clonazepam recommended when
may increase concentrations of co-administering boosted
clonazepam. (CYP3A inhibition) PREZISTA with clonazepam.
ANTIDEPRESSANTS
Paroxetine paroxetine AUC ↓ 39% If antidepressants are
20 mg once daily paroxetine Cmin ↓ 37% co-administered with boosted
paroxetine Cmax ↓ 36% PREZISTA, the recommended
#
darunavir AUC ↔ approach is a dose titration of the
#
darunavir Cmin ↔ antidepressant based on a clinical
# assessment of antidepressant
darunavir Cmax ↔
Sertraline response. In addition, patients on a
sertraline AUC ↓ 49%
50 mg once daily stable dose of these antidepressants
sertraline Cmin ↓ 49% who start treatment with boosted
sertraline Cmax ↓ 44% PREZISTA should be monitored
#
darunavir AUC ↔ for antidepressant response.
#
darunavir Cmin ↓ 6%
#
darunavir Cmax ↔
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): paroxetine (HOS-086246) carbamazepine (HOS-085618) cobicistat (HOS-088111) clonazepam (HOS-116372) sertraline (HOS-086247)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-07-26T09:44:00Z · SHA-256 457dafbe8b3b9cee45b9ca7b46919ded598e0d0cd16715525d161e54f80b9117 · Passage fee71dc165cb305da55981cba92045f504e6465477968e08d166b14a17e467a2 · Zeichen 37100–39117 im Abschnitt
Wechselwirkungen · Prezista
PREZISTA 75 mg film-coated tablets PREZISTA 150 mg film-coated tablets PREZISTA 600 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 58
HOS-116520 · Präparat HOS-094447
Clopidogrel Not studied. Co-administration of Co-administration of clopidogrel
clopidogrel with boosted PREZISTA is with boosted PREZISTA is not
expected to decrease clopidogrel active recommended. Use of other
metabolite plasma concentration, which antiplatelets not affected by CYP
may reduce the antiplatelet activity of inhibition or induction (e.g.
clopidogrel. prasugrel) is recommended.
Warfarin Not studied. Warfarin concentrations may It is recommended that the
be affected when co-administered with international normalised ratio
darunavir with low dose ritonavir. (INR) be monitored when warfarin
is combined with PREZISTA
co-administered with low dose
ritonavir.
ANTICONVULSANTS
Phenobarbital Not studied. Phenobarbital and phenytoin PREZISTA co-administered with
Phenytoin are expected to decrease plasma low dose ritonavir should not be
concentrations of darunavir and its used in combination with these
pharmacoenhancer. medicines.
(induction of CYP450 enzymes)
Carbamazepine carbamazepine AUC ↑ 45% No dose adjustment for
200 mg twice daily carbamazepine Cmin ↑ 54% PREZISTA/ritonavir is
carbamazepine Cmax ↑ 43% recommended. If there is a need to
darunavir AUC ↔ combine PREZISTA/ritonavir and
darunavir Cmin ↓ 15% carbamazepine, patients should be
darunavir Cmax ↔ monitored for potential
carbamazepine-related adverse
events. Carbamazepine
concentrations should be
monitored and its dose should be
titrated for adequate response.
Based upon the findings, the
carbamazepine dose may need to
be reduced by 25% to 50% in the
presence of PREZISTA/ritonavir.
Clonazepam Not studied. Co-administration of Clinical monitoring is
boosted PREZISTA with clonazepam recommended when
may increase concentrations of co-administering boosted
clonazepam. (CYP3A inhibition) PREZISTA with clonazepam.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): phenobarbital (HOS-085617) carbamazepine (HOS-085618) clonazepam (HOS-116372) clopidogrel (HOS-087927) prasugrel (HOS-112066) ritonavir (HOS-084521) phenytoin (HOS-084531) warfarin (HOS-085950)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-07-26T09:44:00Z · SHA-256 457dafbe8b3b9cee45b9ca7b46919ded598e0d0cd16715525d161e54f80b9117 · Passage 850ad5ed2985c0e66d0e474be614ba921c2559aea01cb8443674697805799b26 · Zeichen 25971–29352 im Abschnitt
Wechselwirkungen · Prezista
PREZISTA 400 mg film-coated tablets PREZISTA 800 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 99
HOS-116611 · Präparat HOS-094447
The use of carbamazepine with
PREZISTA co-administered with
cobicistat is contraindicated (see
section 4.3).
Clonazepam Not studied. Co-administration of Clinical monitoring is
boosted PREZISTA with clonazepam recommended when
may increase concentrations of co-administering boosted
clonazepam. (CYP3A inhibition) PREZISTA with clonazepam.
ANTIDEPRESSANTS
Paroxetine paroxetine AUC ↓ 39% If antidepressants are
20 mg once daily paroxetine Cmin ↓ 37% co-administered with boosted
paroxetine Cmax ↓ 36% PREZISTA, the recommended
#
darunavir AUC ↔ approach is a dose titration of the
#
darunavir Cmin ↔ antidepressant based on a clinical
# assessment of antidepressant
darunavir Cmax ↔
Sertraline response. In addition, patients on a
sertraline AUC ↓ 49%
50 mg once daily stable dose of these antidepressants
sertraline Cmin ↓ 49% who start treatment with boosted
sertraline Cmax ↓ 44% PREZISTA should be monitored
#
darunavir AUC ↔ for antidepressant response.
#
darunavir Cmin ↓ 6%
#
darunavir Cmax ↔
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): paroxetine (HOS-086246) carbamazepine (HOS-085618) cobicistat (HOS-088111) clonazepam (HOS-116372) sertraline (HOS-086247)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-07-26T09:44:00Z · SHA-256 457dafbe8b3b9cee45b9ca7b46919ded598e0d0cd16715525d161e54f80b9117 · Passage b34fa59b9b5d780f603efdefff41afa991e73305d8f192f74aaedad00500717a · Zeichen 36670–38651 im Abschnitt
Wechselwirkungen · Votubia
Votubia 2.5 mg tablets Votubia 5 mg tablets Votubia 10 mg tablets · Abschnitt 4.5 · PDF-Seite 13
HOS-214265 · Präparat HOS-155312
In EXIST-3 (Study CRAD001M2304), everolimus increased pre-dose concentrations of the
antiepileptics carbamazepine, clobazam, and the clobazam metabolite N-desmethylclobazam by about
10%. The increase in the pre-dose concentrations of these antiepileptics may not be clinically
significant but dose adjustments for antiepileptics with a narrow therapeutic index, e.g carbamazepine,
may be considered. Everolimus had no impact on pre-dose concentrations of antiepileptics that are
substrates of CYP3A4 (clonazepam, diazepam, felbamate and zonisamide).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): felbamate (HOS-110308) zonisamide (HOS-113349) carbamazepine (HOS-085618) diazepam (HOS-085904) clonazepam (HOS-116372) clobazam (HOS-115305)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-20T17:40:00Z · SHA-256 252b066ec590fdab1f3eb7eccacdb5c7e91ec79421c970096d1b5261820faba4 · Passage b4c2343c971adfce7a75aba39924472177c65c41b33f69eff97d2884460f8bc4 · Zeichen 14980–15529 im Abschnitt
Wechselwirkungen · Votubia
Votubia 1 mg dispersible tablets Votubia 2 mg dispersible tablets Votubia 3 mg dispersible tablets Votubia 5 mg dispersible tablets · Abschnitt 4.5 · PDF-Seite 40
HOS-214315 · Präparat HOS-155312
In EXIST-3 (Study CRAD001M2304), everolimus increased pre-dose concentrations of the
antiepileptics carbamazepine, clobazam, and the clobazam metabolite N-desmethylclobazam by about
10%. The increase in the pre-dose concentrations of these antiepileptics may not be clinically
significant but dose adjustments for antiepileptics with a narrow therapeutic index, e.g carbamazepine,
may be considered. Everolimus had no impact on pre-dose concentrations of antiepileptics that are
substrates of CYP3A4 (clonazepam, diazepam, felbamate and zonisamide).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): felbamate (HOS-110308) zonisamide (HOS-113349) carbamazepine (HOS-085618) diazepam (HOS-085904) clonazepam (HOS-116372) clobazam (HOS-115305)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-20T17:40:00Z · SHA-256 252b066ec590fdab1f3eb7eccacdb5c7e91ec79421c970096d1b5261820faba4 · Passage b4c2343c971adfce7a75aba39924472177c65c41b33f69eff97d2884460f8bc4 · Zeichen 11041–11590 im Abschnitt
Wechselwirkungen · Fycompa
Fycompa 2 mg film-coated tablets Fycompa 4 mg film-coated tablets Fycompa 6 mg film-coated tablets Fycompa 8 mg film-coated tablets Fycompa 10 mg film-coated tablets Fycompa 12 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 9
HOS-125858 · Präparat HOS-096179
AED Influence of AED on Fycompa Influence of Fycompa on AED
coadministered concentration concentration
Carbamazepine 3 fold decrease <10% decrease
Clobazam No influence <10% decrease
Clonazepam No influence No influence
Lamotrigine No influence <10% decrease
Levetiracetam No influence No influence
Oxcarbazepine 2 fold decrease 35% increase 1)
Phenobarbital 20% decrease No influence
Phenytoin 2 fold decrease No influence
Topiramate 20% decrease No influence
Valproic Acid No influence <10% decrease
Zonisamide No influence No influence
1) Active metabolite monohydroxycarbazepine was not assessed.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lamotrigine (HOS-086242) zonisamide (HOS-113349) topiramate (HOS-110310) phenobarbital (HOS-085617) valproic acid (HOS-088515) carbamazepine (HOS-085618) clonazepam (HOS-116372) clobazam (HOS-115305) oxcarbazepine (HOS-110224) phenytoin (HOS-084531) levetiracetam (HOS-090742)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-05-26T10:26:00Z · SHA-256 b5542bbc20a489b9730fd4bf2ab7b210c2adb03b3f707d2db6edd804a3f94228 · Passage 647b74f1f5a644667e9a8063823957e8fd2e4109c0c3dd9c6238f2d38b637f3d · Zeichen 1607–2679 im Abschnitt
Wechselwirkungen · Fycompa
Fycompa 2 mg film-coated tablets Fycompa 4 mg film-coated tablets Fycompa 6 mg film-coated tablets Fycompa 8 mg film-coated tablets Fycompa 10 mg film-coated tablets Fycompa 12 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 9–10
HOS-125863 · Präparat HOS-096179
9
(2-fold), which are known inducers of enzymes of metabolism (see section 5.2). This effect should be
taken into account and managed when adding or withdrawing these anti-epileptic drugs from a
patient’s treatment regimen. Clonazepam, levetiracetam, phenobarbital, topiramate, zonisamide,
clobazam, lamotrigine and valproic acid did not affect to a clinically relevant manner the clearance of
Fycompa.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lamotrigine (HOS-086242) zonisamide (HOS-113349) topiramate (HOS-110310) phenobarbital (HOS-085617) valproic acid (HOS-088515) clonazepam (HOS-116372) clobazam (HOS-115305) levetiracetam (HOS-090742)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-05-26T10:26:00Z · SHA-256 b5542bbc20a489b9730fd4bf2ab7b210c2adb03b3f707d2db6edd804a3f94228 · Passage e745f17825e615006ee5ebd992b92d6720733933f295bdbde789d0951a9fb36b · Zeichen 3027–3430 im Abschnitt
Wechselwirkungen · Fycompa
Fycompa 2 mg film-coated tablets Fycompa 4 mg film-coated tablets Fycompa 6 mg film-coated tablets Fycompa 8 mg film-coated tablets Fycompa 10 mg film-coated tablets Fycompa 12 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 10
HOS-125864 · Präparat HOS-096179
In a population pharmacokinetic analysis of patients with partial-onset seizures, Fycompa did not
affect to a clinically relevant manner the clearance of clonazepam, levetiracetam, phenobarbital,
phenytoin, topiramate, zonisamide, carbamazepine, clobazam, lamotrigine and valproic acid, at the
highest perampanel dose evaluated (12 mg/day).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lamotrigine (HOS-086242) zonisamide (HOS-113349) topiramate (HOS-110310) phenobarbital (HOS-085617) valproic acid (HOS-088515) carbamazepine (HOS-085618) clonazepam (HOS-116372) clobazam (HOS-115305) phenytoin (HOS-084531) levetiracetam (HOS-090742)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-05-26T10:26:00Z · SHA-256 b5542bbc20a489b9730fd4bf2ab7b210c2adb03b3f707d2db6edd804a3f94228 · Passage 36efea4d6a919f522d99498e96e93543d04877d49295dea5cd84f4081dd78b75 · Zeichen 3432–3772 im Abschnitt
Wechselwirkungen · Fycompa
Fycompa 0.5 mg/ml oral suspension · Abschnitt 4.5 · PDF-Seite 29–30
HOS-125902 · Präparat HOS-096179
29
AED Influence of AED on Fycompa Influence of Fycompa on AED
coadministered concentration concentration
Carbamazepine 3 fold decrease <10% decrease
Clobazam No influence <10% decrease
Clonazepam No influence No influence
Lamotrigine No influence <10% decrease
Levetiracetam No influence No influence
Oxcarbazepine 2 fold decrease 35% increase 1)
Phenobarbital 20% decrease No influence
Phenytoin 2 fold decrease No influence
Topiramate 20% decrease No influence
Valproic Acid No influence <10% decrease
Zonisamide No influence No influence
1) Active metabolite monohydroxycarbazepine was not assessed.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lamotrigine (HOS-086242) zonisamide (HOS-113349) topiramate (HOS-110310) phenobarbital (HOS-085617) valproic acid (HOS-088515) carbamazepine (HOS-085618) clonazepam (HOS-116372) clobazam (HOS-115305) oxcarbazepine (HOS-110224) phenytoin (HOS-084531) levetiracetam (HOS-090742)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-05-26T10:26:00Z · SHA-256 b5542bbc20a489b9730fd4bf2ab7b210c2adb03b3f707d2db6edd804a3f94228 · Passage 27257b38863890a7e9dcd5ec83e5495cfc50cf21047cba94476f502d1cb8f8f6 · Zeichen 1653–2734 im Abschnitt
Wechselwirkungen · Fycompa
Fycompa 0.5 mg/ml oral suspension · Abschnitt 4.5 · PDF-Seite 30
HOS-125903 · Präparat HOS-096179
Based on the results from the population pharmacokinetic analysis of patients with partial-onset
seizures and patients with primary generalised tonic-clonic seizures the total clearance of Fycompa
was increased when co-administered with carbamazepine (3-fold), and phenytoin or oxcarbazepine
(2-fold), which are known inducers of enzymes of metabolism (see section 5.2). This effect should be
taken into account and managed when adding or withdrawing these anti-epileptic drugs from a
patient’s treatment regimen. Clonazepam, levetiracetam, phenobarbital, topiramate, zonisamide,
clobazam, lamotrigine and valproic acid did not affect to a clinically relevant manner the clearance of
Fycompa.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lamotrigine (HOS-086242) zonisamide (HOS-113349) topiramate (HOS-110310) phenobarbital (HOS-085617) valproic acid (HOS-088515) carbamazepine (HOS-085618) clonazepam (HOS-116372) clobazam (HOS-115305) oxcarbazepine (HOS-110224) phenytoin (HOS-084531) levetiracetam (HOS-090742)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-05-26T10:26:00Z · SHA-256 b5542bbc20a489b9730fd4bf2ab7b210c2adb03b3f707d2db6edd804a3f94228 · Passage 0082e100157a5b8d067c8c128173d1d009cc83c573888e5b8dcb2b89cb2beac5 · Zeichen 2736–3428 im Abschnitt
Wechselwirkungen · Fycompa
Fycompa 0.5 mg/ml oral suspension · Abschnitt 4.5 · PDF-Seite 30
HOS-125904 · Präparat HOS-096179
In a population pharmacokinetic analysis of patients with partial-onset seizures, Fycompa did not
affect to a clinically relevant manner the clearance of clonazepam, levetiracetam, phenobarbital,
phenytoin, topiramate, zonisamide, carbamazepine, clobazam, lamotrigine and valproic acid, at the
highest perampanel dose evaluated (12 mg/day).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lamotrigine (HOS-086242) zonisamide (HOS-113349) topiramate (HOS-110310) phenobarbital (HOS-085617) valproic acid (HOS-088515) carbamazepine (HOS-085618) clonazepam (HOS-116372) clobazam (HOS-115305) phenytoin (HOS-084531) levetiracetam (HOS-090742)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-05-26T10:26:00Z · SHA-256 b5542bbc20a489b9730fd4bf2ab7b210c2adb03b3f707d2db6edd804a3f94228 · Passage 36efea4d6a919f522d99498e96e93543d04877d49295dea5cd84f4081dd78b75 · Zeichen 3430–3770 im Abschnitt
Wechselwirkungen · Xtandi
Xtandi - 40 mg soft capsules · Abschnitt 4.5 · PDF-Seite 6
HOS-127857 · Präparat HOS-096479
• Analgesics (e.g. fentanyl, tramadol)
• Antibiotics (e.g. clarithromycin, doxycycline)
• Anticancer agents (e.g. cabazitaxel)
• Antiepileptics (e.g. carbamazepine, clonazepam, phenytoin, primidone, valproic acid)
• Antipsychotics (e.g. haloperidol)
• Antithrombotics (e.g. acenocoumarol, warfarin, clopidogrel)
• Betablockers (e.g. bisoprolol, propranolol)
• Calcium channel blockers (e.g. diltiazem, felodipine, nicardipine, nifedipine, verapamil)
• Cardiac glycosides (e.g. digoxin)
• Corticosteroids (e.g. dexamethasone, prednisolone)
• HIV antivirals (e.g. indinavir, ritonavir)
• Hypnotics (e.g. diazepam, midazolam, zolpidem)
• Immunosuppressant (e.g. tacrolimus)
• Proton pump inhibitor (e.g. omeprazole)
• Statins metabolised by CYP3A4 (e.g. atorvastatin, simvastatin)
• Thyroid agents (e.g. levothyroxine)
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): doxycycline (HOS-127860) indinavir (HOS-084518) diltiazem (HOS-086288) prednisolone (HOS-086337) nifedipine (HOS-086289) nicardipine (HOS-090619) valproic acid (HOS-088515) atorvastatin (HOS-086304) felodipine (HOS-108908) carbamazepine (HOS-085618) simvastatin (HOS-086158) digoxin (HOS-086172) diazepam (HOS-085904) calcium (HOS-085615) clonazepam (HOS-116372) zolpidem (HOS-086327) dexamethasone (HOS-084535) bisoprolol (HOS-127867) clopidogrel (HOS-087927) clarithromycin (HOS-084517) tacrolimus (HOS-085202) cabazitaxel (HOS-124028) fentanyl (HOS-086196) haloperidol (HOS-085602) ritonavir (HOS-084521) propranolol (HOS-084529) acenocoumarol (HOS-109456) phenytoin (HOS-084531) warfarin (HOS-085950) midazolam (HOS-086167) primidone (HOS-090551) omeprazole (HOS-085912) tramadol (HOS-112871) verapamil (HOS-090602) levothyroxine (HOS-086339)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-29T10:07:00Z · SHA-256 2bf5e532360d917a40a8717a4c2398563991ca5e2d824233a2adf92bb006bfb9 · Passage 1a9d62c15c13d5c61581dad54a11c2cf2c5b042e25c19573444c32687d55e83b · Zeichen 3973–4850 im Abschnitt
Wechselwirkungen · Xtandi
Xtandi - 40 mg film-coated tablets Xtandi - 80 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 36
HOS-127925 · Präparat HOS-096479
• Analgesics (e.g. fentanyl, tramadol)
• Antibiotics (e.g. clarithromycin, doxycycline)
• Anticancer agents (e.g. cabazitaxel)
• Antiepileptics (e.g. carbamazepine, clonazepam, phenytoin, primidone, valproic acid)
• Antipsychotics (e.g. haloperidol)
• Antithrombotics (e.g. acenocoumarol, warfarin, clopidogrel)
• Betablockers (e.g. bisoprolol, propranolol)
• Calcium channel blockers (e.g. diltiazem, felodipine, nicardipine, nifedipine, verapamil)
• Cardiac glycosides (e.g. digoxin)
• Corticosteroids (e.g. dexamethasone, prednisolone)
• HIV antivirals (e.g. indinavir, ritonavir)
• Hypnotics (e.g. diazepam, midazolam, zolpidem)
• Immunosuppressant (e.g. tacrolimus)
• Proton pump inhibitor (e.g. omeprazole)
• Statins metabolised by CYP3A4 (e.g. atorvastatin, simvastatin)
• Thyroid agents (e.g. levothyroxine)
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): doxycycline (HOS-127860) indinavir (HOS-084518) diltiazem (HOS-086288) prednisolone (HOS-086337) nifedipine (HOS-086289) nicardipine (HOS-090619) valproic acid (HOS-088515) atorvastatin (HOS-086304) felodipine (HOS-108908) carbamazepine (HOS-085618) simvastatin (HOS-086158) digoxin (HOS-086172) diazepam (HOS-085904) calcium (HOS-085615) clonazepam (HOS-116372) zolpidem (HOS-086327) dexamethasone (HOS-084535) bisoprolol (HOS-127867) clopidogrel (HOS-087927) clarithromycin (HOS-084517) tacrolimus (HOS-085202) cabazitaxel (HOS-124028) fentanyl (HOS-086196) haloperidol (HOS-085602) ritonavir (HOS-084521) propranolol (HOS-084529) acenocoumarol (HOS-109456) phenytoin (HOS-084531) warfarin (HOS-085950) midazolam (HOS-086167) primidone (HOS-090551) omeprazole (HOS-085912) tramadol (HOS-112871) verapamil (HOS-090602) levothyroxine (HOS-086339)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-29T10:07:00Z · SHA-256 2bf5e532360d917a40a8717a4c2398563991ca5e2d824233a2adf92bb006bfb9 · Passage 1a9d62c15c13d5c61581dad54a11c2cf2c5b042e25c19573444c32687d55e83b · Zeichen 3974–4851 im Abschnitt
Wechselwirkungen · Busulfan Fresenius Kabi
Busulfan Fresenius Kabi 6 mg/ml concentrate for solution for infusion · Abschnitt 4.5 · PDF-Seite 7
HOS-129997 · Präparat HOS-096825
Either phenytoin or benzodiazepines were administered for seizure prophylaxis in
patients participating to the clinical trials conducted with intravenous busulfan (see
section 4.2 and 4.4).
The concomitant systemic administration of phenytoin to patients receiving high-dose of oral
busulfan has been reported to increase busulfan clearance, due to induction of
glutathion-S-transferase whereas no interaction has been reported when benzodiazepines such
as diazepam, clonazepam or lorazepam have been used to prevent seizures with high-dose
busulfan.
No evidence of an induction effect of phenytoin has been seen on busulfan data.
A phase II clinical trial was performed to evaluate the influence of seizure prophylaxis
treatment on intravenous busulfan pharmacokinetics. In this study, 24 adult patients received
clonazepam (0.025-0.03 mg/kg/day as IV continuous infusions) as anticonvulsant therapy and
the PK data of these patients were compared to historical data collected in patients treated with
phenytoin. The analysis of data through a population pharmacokinetic method indicated no
difference on intravenous busulfan clearance between phenytoin and clonazepam based therapy
and therefore similar busulfan plasma exposures were achieved whatever the type of seizure
prophylaxis.
No interaction was observed when busulfan was combined with 5 HT3 antiemetics such as
ondansetron or granisetron.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): granisetron (HOS-086051) lorazepam (HOS-085981) diazepam (HOS-085904) clonazepam (HOS-116372) ondansetron (HOS-086052) phenytoin (HOS-084531)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-07-01T12:05:00Z · SHA-256 803007b850189812dae1406bc9fec1c869aaeaaacf0104c26b1fa84613ab3fe2 · Passage b8ee5b020de00b86b5a78ecc3b4b397a77f16f462a20a65fb613eafbd484fbec · Zeichen 2302–3703 im Abschnitt
Wechselwirkungen · Briviact (in Italy: Nubriveo)
Briviact 10 mg film-coated tablets Briviact 25 mg film-coated tablets Briviact 50 mg film-coated tablets Briviact 75 mg film-coated tablets Briviact 100 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 7–8
HOS-132732 · Präparat HOS-097290
7
Table 1: Pharmacokinetic interactions between brivaracetam and other AEDs
AED coadministered Influence of AED on brivaracetam Influence of brivaracetam on
plasma concentration AED plasma concentration
Carbamazepine AUC 29 % ↓ Carbamazepine - None
Cmax 13 % ↓ Carbamazepine-epoxide ↑
No dose adjustment required (See below)
No dose adjustment required.
Clobazam No data available None
Clonazepam No data available None
Lacosamide No data available None
Lamotrigine None None
Levetiracetam None None
Oxcarbazepine None None (monohydroxy derivative,
MHD)
Phenobarbital AUC 19 % ↓ None
No dose adjustment required
Phenytoin AUC 21 % ↓ None
a
No dose adjustment required AUC 20% ↑
a
Cmax 20% ↑
Pregabalin No data available None
Topiramate None None
Valproic acid None None
Zonisamide No data available None
a
based on a study involving the administration of a supratherapeutic dose of 400 mg/day brivaracetam.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lamotrigine (HOS-086242) pregabalin (HOS-112893) zonisamide (HOS-113349) topiramate (HOS-110310) phenobarbital (HOS-085617) valproic acid (HOS-088515) carbamazepine (HOS-085618) clonazepam (HOS-116372) lacosamide (HOS-119434) clobazam (HOS-115305) oxcarbazepine (HOS-110224) phenytoin (HOS-084531) levetiracetam (HOS-090742)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-05-19T16:24:00Z · SHA-256 8b43e201402e087df36cd28aad896b8b68dd1973b788cdf0991029210330f8cc · Passage 72be288fc6f264a208b76e40d3bbbe0736dc14fffd0d02733e55f0e7136a6e11 · Zeichen 4319–6334 im Abschnitt
Wechselwirkungen · Briviact (in Italy: Nubriveo)
Briviact 10 mg/ml oral solution · Abschnitt 4.5 · PDF-Seite 27
HOS-132771 · Präparat HOS-097290
Table 1: Pharmacokinetic interactions between brivaracetam and other AEDs
AED coadministered Influence of AED on brivaracetam Influence of brivaracetam on
plasma concentration AED plasma concentration
Carbamazepine AUC 29 % ↓ Carbamazepine - None
Cmax 13 % ↓ Carbamazepine-epoxide ↑
No dose adjustment required (See below)
No dose adjustment required.
Clobazam No data available None
Clonazepam No data available None
Lacosamide No data available None
Lamotrigine None None
Levetiracetam None None
Oxcarbazepine None None (monohydroxy derivative,
MHD)
Phenobarbital AUC 19 % ↓ None
No dose adjustment required
Phenytoin AUC 21 % ↓ None
a
No dose adjustment required AUC 20% ↑
a
Cmax 20% ↑
Pregabalin No data available None
Topiramate None None
Valproic acid None None
Zonisamide No data available None
a
based on a study involving the administration of a supratherapeutic dose of 400 mg/day brivaracetam
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lamotrigine (HOS-086242) pregabalin (HOS-112893) zonisamide (HOS-113349) topiramate (HOS-110310) phenobarbital (HOS-085617) valproic acid (HOS-088515) carbamazepine (HOS-085618) clonazepam (HOS-116372) lacosamide (HOS-119434) clobazam (HOS-115305) oxcarbazepine (HOS-110224) phenytoin (HOS-084531) levetiracetam (HOS-090742)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-05-19T16:24:00Z · SHA-256 8b43e201402e087df36cd28aad896b8b68dd1973b788cdf0991029210330f8cc · Passage a85359f86ddb15f4c003c78da49ccc7749096d8a1fb461df879c4788092ede93 · Zeichen 4266–6368 im Abschnitt
Wechselwirkungen · Briviact (in Italy: Nubriveo)
Briviact 10 mg/ml solution for injection/infusion · Abschnitt 4.5 · PDF-Seite 43
HOS-132807 · Präparat HOS-097290
Table 1: Pharmacokinetic interactions between brivaracetam and other AEDs
AED coadministered Influence of AED on brivaracetam Influence of brivaracetam on
plasma concentration AED plasma concentration
Carbamazepine AUC 29 % ↓ Carbamazepine - None
Cmax 13 % ↓ Carbamazepine-epoxide ↑
No dose adjustment required (See below)
No dose adjustment required.
Clobazam No data available None
Clonazepam No data available None
Lacosamide No data available None
Lamotrigine None None
Levetiracetam None None
Oxcarbazepine None None (monohydroxy derivative,
MHD)
Phenobarbital AUC 19 % ↓ None
No dose adjustment required
Phenytoin AUC 21 % ↓ None
a
No dose adjustment required AUC 20% ↑
a
Cmax 20% ↑
Pregabalin No data available None
Topiramate None None
Valproic acid None None
Zonisamide No data available None
a
based on a study involving the administration of a supratherapeutic dose of 400 mg/day brivaracetam
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lamotrigine (HOS-086242) pregabalin (HOS-112893) zonisamide (HOS-113349) topiramate (HOS-110310) phenobarbital (HOS-085617) valproic acid (HOS-088515) carbamazepine (HOS-085618) clonazepam (HOS-116372) lacosamide (HOS-119434) clobazam (HOS-115305) oxcarbazepine (HOS-110224) phenytoin (HOS-084531) levetiracetam (HOS-090742)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-05-19T16:24:00Z · SHA-256 8b43e201402e087df36cd28aad896b8b68dd1973b788cdf0991029210330f8cc · Passage a85359f86ddb15f4c003c78da49ccc7749096d8a1fb461df879c4788092ede93 · Zeichen 4263–6365 im Abschnitt
Wechselwirkungen · Darunavir Viatris (previously Darunavir Mylan)
Darunavir Viatris 75 mg film-coated tablets Darunavir Viatris 150 mg film-coated tablets Darunavir Viatris 300 mg film-coated tablets Darunavir Viatris 600 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 14
HOS-134492 · Präparat HOS-097580
Clopidogrel Not studied. Co-administration of Co-administration of clopidogrel
clopidogrel with boosted darunavir is with boosted darunavir is not
expected to decrease clopidogrel active recommended.
metabolite plasma concentration,
which may reduce the antiplatelet Use of other antiplatelets not
activity of clopidogrel. affected by CYP inhibition or
induction (e.g. prasugrel) is
recommended.
Warfarin Not studied. Warfarin concentrations It is recommended that the
may be affected when co-administered international normalised ratio (INR)
with darunavir with low dose ritonavir. be monitored when warfarin is
combined with darunavir co-
administered with low dose
ritonavir.
ANTICONVULSANTS
Phenobarbital Not studied. Phenobarbital and Darunavir co-administered with low
Phenytoin phenytoin are expected to decrease dose ritonavir should not be used in
plasma concentrations of darunavir and combination with these medicines.
its pharmacoenhancer.
(induction of CYP450 enzymes)
Carbamazepine carbamazepine AUC ↑ 45% No dose adjustment for
200 mg twice daily carbamazepine Cmin ↑ 54% darunavir/ritonavir is
carbamazepine Cmax ↑ 43% recommended. If there is a need to
darunavir AUC ↔ combine darunavir/ritonavir and
darunavir Cmin ↓ 15% carbamazepine, patients should be
darunavir Cmax ↔ monitored for potential
carbamazepine-related adverse
events. Carbamazepine
concentrations should be monitored
and its dose should be titrated for
adequate response.
Based upon the findings, the
carbamazepine dose may need to be
reduced by 25% to 50% in the
presence of darunavir/ritonavir.
Clonazepam Not studied. Co-administration of Clinical monitoring is
boosted darunavir with clonazepam recommended when co-
may increase concentrations of administering boosted darunavir
clonazepam. (CYP3A inhibition) with clonazepam.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): phenobarbital (HOS-085617) carbamazepine (HOS-085618) clonazepam (HOS-116372) clopidogrel (HOS-087927) prasugrel (HOS-112066) ritonavir (HOS-084521) phenytoin (HOS-084531) warfarin (HOS-085950)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-20T12:32:00Z · SHA-256 50f4771a683f17214737463c6df88a158b1e699bbb9916413602e547e369e804 · Passage 18f88a1538e549d8b6880998a637a7940712c9de8be51f9feea7646da83d20c9 · Zeichen 26132–29743 im Abschnitt
Wechselwirkungen · Darunavir Viatris (previously Darunavir Mylan)
Darunavir Viatris 400 mg film-coated tablets Darunavir Viatris 800 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 56
HOS-134617 · Präparat HOS-097580
The use of carbamazepine with
darunavir co-administered with
cobicistat is contraindicated (see
section 4.3).
Clonazepam Not studied. Co-administration of Clinical monitoring is recommended
boosted darunavir with clonazepam when co-administering boosted
may increase concentrations of darunavir with clonazepam.
clonazepam. (CYP3A inhibition)
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): carbamazepine (HOS-085618) cobicistat (HOS-088111) clonazepam (HOS-116372)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-20T12:32:00Z · SHA-256 50f4771a683f17214737463c6df88a158b1e699bbb9916413602e547e369e804 · Passage 95779241b77685b63403495fe4f71d72c2cd739d5e1af05a5eff4f24ed488ebe · Zeichen 35027–35664 im Abschnitt
Wechselwirkungen · Symtuza
Symtuza 800 mg/150 mg/200 mg/10 mg film-coated tablets Symtuza 675 mg/150 mg/200 mg/10 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 11
HOS-138482 · Präparat HOS-098200
Clopidogrel Based on theoretical Co-administration of Symtuza
considerations co-administration of with clopidogrel is not
Symtuza with clopidogrel is recommended. Use of other
expected to decrease clopidogrel antiplatelets not affected by CYP
active metabolite plasma inhibition or induction (e.g.
concentration, which may reduce prasugrel) is recommended (see
the antiplatelet activity of section 4.3).
clopidogrel.
Warfarin Based on theoretical It is recommended that the
considerations DRV/COBI may international normalised ratio
alter warfarin plasma (INR) be monitored when
concentrations. warfarin is co-administered with
Symtuza.
ANTICONVULSANTS
Carbamazepine Based on theoretical Co-administration of Symtuza
Phenobarbital considerations these and these anticonvulsants is
Phenytoin anticonvulsants are expected to contraindicated (see section 4.3).
decrease darunavir and/or
cobicistat and/or tenofovir
alafenamide plasma
concentrations.
(CYP3A and/or P-gp induction).
Oxcarbazepine Co-administration of Symtuza
with oxcarbazepine is not
recommended. Alternative
anticonvulsants should be
considered.
Clonazepam Based on theoretical considerations Clinical monitoring is
Symtuza is expected to increase recommended when
concentrations of clonazepam. co-administering Symtuza with
(inhibition of CYP3A) clonazepam.
ANTI-DEPRESSANTS
Herbal supplements Based on theoretical considerations Co-administration of
St. John’s Wort St. John’s Wort is expected to St. John’s Wort and Symtuza is
decrease darunavir and/or contraindicated (see section 4.3).
cobicistat and/or tenofovir
alafenamide plasma
concentrations.
(CYP3A and/or P-gp induction)
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tenofovir (HOS-088083) phenobarbital (HOS-085617) carbamazepine (HOS-085618) clonazepam (HOS-116372) clopidogrel (HOS-087927) prasugrel (HOS-112066) oxcarbazepine (HOS-110224) phenytoin (HOS-084531) warfarin (HOS-085950)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-09-16T11:21:00Z · SHA-256 542f840b29cc7afaff9940b20511550e8d35031b33d95efd774fd49f70f7819d · Passage 187c0fed160e40c7da0a4ce1c8b126337a2665df943610da374a786680424cda · Zeichen 11857–14725 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.